ATGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Adtalem Global Education Inc (soon to be rebranded as Covista) shows potential for long-term growth in the healthcare education sector, supported by positive financial performance and strategic initiatives. However, the current technical indicators suggest a bearish trend, and the price is in a downward movement. For a beginner investor with a long-term horizon, it may be better to wait for stabilization or a clearer upward trend before investing.
The stock is currently in a bearish trend with the MACD histogram at -2.108 (negatively expanding), RSI at 18.51 (indicating oversold conditions), and moving averages showing a bearish alignment (SMA_200 > SMA_20 > SMA_5). The price is near the S1 support level of 92.982, with further downside risk to S2 at 88.411.
Rebranding to Covista with a focus on healthcare education to address workforce shortages.
Strong financial performance in 2026/Q2 with revenue up 12.43% YoY and EPS up 6.57% YoY.
Analyst upgrade by BMO Capital with a raised price target to $138, citing improved marketing efficiency and enrollment funnel conversion.
Current bearish technical indicators and price decline (-2.36% in the regular market session).
Broader market weakness with S&P 500 down 1.54%.
Lack of significant hedge fund or insider trading activity.
In 2026/Q2, the company reported revenue of $503.39M (up 12.43% YoY), net income of $76.38M (up 0.69% YoY), EPS of 2.11 (up 6.57% YoY), and gross margin of 59.19% (up 1.51% YoY). These results indicate steady growth and operational efficiency.
BMO Capital raised the price target to $138 from $120 and maintained an Outperform rating, citing strong results driven by Walden growth and improved marketing efficiency. Analysts are optimistic about enrollment growth in the fall.
